Angiogenic inhibition reduces germinal matrix hemorrhage

Nature Medicine

Volumn 13, Issue 4, 2007, Pages 477-485

  Ballabh, Praveen ^a   Xu, Hongmin ^a   Hu, Furong ^a   Braun, Alex ^a   Smith, Kira ^a   Rivera, Aracelie ^a   Lou, Nanhong ^b   Ungvari, Zoltan ^a   Goldman, Steven A ^b   Csiszar, Anna ^a   Nedergaard, Maiken ^b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CELECOXIB; VANDETANIB; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN HEMORRHAGE; BRAIN REGION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; GESTATIONAL AGE; INTRACRANIAL PRESSURE; LASER CAPTURE MICRODISSECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PREMATURITY; PRIMORDIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; WHITE MATTER;

ABORTED FETUS; ANGIOPOIETIN-2; ANIMALS; BLOTTING, WESTERN; BRAIN; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; INFANT, PREMATURE; INTRACRANIAL HEMORRHAGES; NEOVASCULARIZATION, PHYSIOLOGIC; PIPERIDINES; PYRAZOLES; QUINAZOLINES; RABBITS; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ORYCTOLAGUS CUNICULUS;

EID: 34147097891     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1558     Document Type: Article

References (48)

1. Heuchan, A.M., Evans, N., Henderson Smart, D.J. & Simpson, J.M. Perinatal risk factors for major intraventricular haemorrhage in the Australian and New Zealand Neonatal Network, 1995-97. Arch. Dis. Child. Fetal Neonatal Ed. 86, F86-F90 (2002).
2. The Vermont-Oxford Trials Network. Very low birth weight outcomes for 1990. Investigators of the Vermont-Oxford Trial Network Database Project. Pediatrics 91, 540-545 (1993).
3. Ballabh, P., Braun, A. & Nedergaard, M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1-13 (2004).
4. du Plessis, A.J. & Volpe, J.J. Perinatal brain injury in the preterm and term newborn. Curr. Opin. Neurol. 15, 151-157 (2002).
5. Ballabh, P., Braun, A. & Nedergaard, M. Anatomic analysis of blood vessels in germinal matrix, cerebral cortex, and white matter in developing infants. Pediatr. Res. 56, 117-124 (2004).
6. Vates, G.E., Hashimoto, T., Young, W.L. & Lawton, M.T. Angiogenesis in the brain during development: the effects of vascular endothelial growth factor and angiopoietin-2 in an animal model. J. Neurosurg. 103, 136-145 (2005).
7. Wong, C.G., Rich, K.A., Liaw, L.H., Hsu, H.T. & Berns, M.W. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr. Eye Res. 22, 140-147 (2001).
8. Ferrara, N., Gerber, H.P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003).
9. Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 9, 653-660 (2003).
10. Zhu, Y. et al. Angiopoietin-2 facilitates vascular endothelial growth factor-induced angiogenesis in the mature mouse brain. Stroke 36, 1533-1537 (2005).
11. Yancopoulos, G.D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248 (2000).
12. Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-1180 (1996).
13. Hammes, H.P. et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53, 1104-1110 (2004).
14. Maisonpierre, P.C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997).
15. Scharpfenecker, M., Fiedler, U., Reiss, Y. & Augustin, H.G. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J. Cell Sci. 118, 771-780 (2005).
16. Hanahan, D. Signaling vascular morphogenesis and maintenance. Science 277, 48-50 (1997).
17. Jain, R.K. Molecular regulation of vessel maturation. Nat. Med. 9, 685-693 (2003).
18. Wang, D., Buchanan, F.G., Wang, H., Dey, S.K. & DuBois, R.N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 65, 1822-1829 (2005).
19. Pichiule, P., Chavez, J.C. & LaManna, J.C. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J. Biol. Chem. 279, 12171-12180 (2004).
20. Wu, Y.L., Fu, S.L., Zhang, Y.P., Qiao, M.M. & Chen, Y. Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts. Biomed. Pharmacother. 59 (suppl. 2), S289-S292 (2005).
21. Masferrer, J.L. et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60, 1306-1311 (2000).
22. Dembo, G., Park, S.B. & Kharasch, E.D. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 102, 409-415 (2005).
23. Hartleroad, J.Y. et al. Effect of maternal administration of selective cyclooxygenase (COX)-2 inhibitors on renal size, growth factors, proteinases, and COX-2 secretion in the fetal rabbit. Biol. Neonate 87, 246-253 (2005).
24. Stika, C.S. et al. A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am. J. Obstet. Gynecol. 187, 653-660 (2002).
25. Herbst, R.S. et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20, 3792-3803 (2002).
26. Virgintino, D. et al. VEGF expression is developmentally regulated during human brain angiogenesis. Histochem. Cell Biol. 119, 227-232 (2003).
27. Mayer, H. et al. Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J. Cell. Biochem. 95, 827-839 (2005).
28. Lorenzo, A.V., Welch, K. & Conner, S. Spontaneous germinal matrix and intraventricular hemorrhage in prematurely born rabbits. J. Neurosurg. 56, 404-410 (1982).
29. Leahy, K.M. et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62, 625-631 (2002).
30. Sanborn, R. & Blanke, C.D. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust? Semin. Oncol. 32, 69-75 (2005).
31. Schnurch, H. & Risau, W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 119, 957-968 (1993).
32. Key, G. et al. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab. Invest. 68, 629-636 (1993).
33. Isobe, K. et al. Measurement of cerebral oxygenation in neonates after vaginal delivery and cesarean section using full-spectrum near infrared spectroscopy. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 132, 133-138 (2002).
34. Alvarez-Soria, M.A. et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann. Rheum. Dis. 65, 998-1005 (2006).
35. El-Rayes, B.F., Ali, S., Sarkar, F.H. & Philip, P.A. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 3, 1421-1426 (2004).
36. Conner, E.S., Lorenzo, A.V., Welch, K. & Dorval, B. The role of intracranial hypotension in neonatal intraventricular hemorrhage. J. Neurosurg. 58, 204-209 (1983).
37. Papile, L.A., Burstein, J., Burstein, R. & Koffler, H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J. Pediatr. 92, 529-534 (1978).
38. Muscara, M.N., Vergnolle, N., Lovren, F., Triggle, C.R., Elliott, S.N., Asfaha, S. & Wallace, J.L. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br. J. Pharmacol. 129, 1423-1430 (2000).
39. Tommiska, V. et al. A national short-term follow-up study of extremely low birth weight infants born in Finland in 1996-1997. Pediatrics 107, E2 (2001).
40. Beverley, D.W., Chance, G.W. & Coates, C.F. Intraventricular haemorrhage-timing of occurrence and relationship to perinatal events. Br. J. Obstet. Gynaecol. 91, 1007-1013 (1984).
41. Tsiantos, A. et al. Intracranial hemorrhage in the prematurely born infant. Timing of clots and evaluation of clinical signs and symptoms. J. Pediatr. 85, 854-859 (1974).
42. Sawaoka, H. et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab. Invest. 79, 1469-1477 (1999).
43. Amrite, A.C., Ayalasomayajula, S.P., Cheruvu, N.P. & Kompella, U.B. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47, 1149-1160 (2006).
44. Fukuda, R., Kelly, B. & Semenza, G.L. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 63, 2330-2334 (2003).
45. Lukiw, W.J. et al. Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest. Ophthalmol. Vis. Sci. 44, 4163-4170 (2003).
46. Sakai, M. et al. Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery. Mol. Hum. Reprod. 7, 595-602 (2001).
47. The Boulder Committee. Embryonic vertebrate central nervous system: revised terminology. Anat. Rec. 28, 3019-3024 (1970).
48. Ballabh, P., Hu, F., Kumarasiri, M., Braun, A. & Nedergaard, M. Development of tight junction molecules in blood vessels of germinal matrix, cerebral cortex, and white matter. Pediatr. Res. 58, 791-798 (2005).